Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
ADVM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.07 - $12.09
Previous CloseN/A
Volume79.70K
Average Volume (3M)154.78K
Market Cap
$71.35M
Enterprise Value$66.57M
Total Cash (Recent Filing)$50.68M
Total Debt (Recent Filing)$14.00K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding20,802,464
10 Day Avg. Volume174,162
30 Day Avg. Volume154,779
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)106.09
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-32.57
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$17.50Price Target Upside497.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Adverum Biotechnologies News
PremiumCompany Announcements
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
PremiumCompany Announcements
Adverum Biotechnologies Delays Yearly Report FilingPremiumCompany Announcements
Adverum Biotechnologies Faces Subtenant Default Situation---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 3 ARTEMIS trial for Ixo-vec includes both treatment-naïve and previously treated wet AMD patients, which can reflect the broad real-world wet AMD patient population.
Financial PerformanceThe $125.7M in cash and equivalents is anticipated to fund operations into the second half of 2025, supporting the ongoing pivotal program.
Product PotentialAnalyst maintains an outperform rating on ADVM due to a bullish view on ixo-vec representing a best-in-class product and a potential global sales opportunity exceeding $2 billion.
Bears Say
Cost ImplicationsThe price target has been adjusted from $20 to $16 due to the assumed cost of the newly disclosed first Phase 3 study and current cash considerations.
Funding ConcernsThere is a major stock overhang due to management not solving how the Phase 3 ixo-vec program will be funded.
---
Ownership Overview
22.11% Insiders
13.38% Mutual Funds
0.40% Other Institutional Investors
53.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADVM FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest stock price was $3.07 and its highest was $12.09 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Adverum Biotechnologies’s market cap is $71.35M.
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is May 08, 2025 which is in 20 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Apr 15, 2025. The company reported -$1.434 earnings per share for the quarter, beating the consensus estimate of -$1.932 by $0.498.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,802,464 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$1.434 in its last earnings report, beating expectations of -$1.932. Following the earnings report the stock price went down -5.831%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Currently, no hedge funds are holding shares in ADVM
---
Adverum Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (497.27% Upside)
$17.50 (497.27% Upside)
Blogger Sentiment
Bullish
ADVM Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.75%
12-Months-Change
Fundamentals
Return on Equity
-144.41%
Trailing 12-Months
Asset Growth
19.11%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
---
ADVM Stock 12 Month Forecast
Average Price Target
$17.50
▲(497.27% Upside)
Technical Analysis
IGM Biosciences
―
Elicio Therapeutics
―
Adagene
―
TScan Therapeutics
―
Adlai Nortye Ltd. Sponsored ADR
―
Best Analysts Covering ADVM
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-46.70%
reiterated a buy rating 5 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -46.70% per trade.
---